

STANDARD GLOBAL REPORT

Date of publication: 30-May-2024

	Full Name	HCPs: City of Principal Practice HCOs: City where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier OPTIONAL	Contribution to costs of Events			Fee for service and consultancy			TOTAL OPTIONAL	
						Donations and Grants to HCOs	Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees			Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract
HCPs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
	BECKER, Marianne	Luxembourg	LU	Rue Nicolas Ernest Barble 4.		N/A	N/A		486.00			486.00	
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
	Aggregate amount attributable to transfers of value to such Recipients						N/A	N/A					
	Number of Recipients in aggregate disclosure						N/A	N/A					
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed						N/A	N/A					N/A	
HCOs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
	Aggregate amount attributable to transfers of value to such Recipients							900.00					900.00
	Number of Recipients in aggregate disclosure							1					1
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed							100.00%					N/A	
R&D	AGGREGATE DISCLOSURE												
	Research and development											1,386.00	



Transparency Reporting at Kyowa Kirin Methodological Note for 2023 data

1. Introduction

Kyowa Kirin Pharma B.V. is committed to supporting healthcare and the development of patient care across Luxembourg. We are pleased to do this through providing funds to Healthcare Organizations (HCOs) or Healthcare Practitioners (HCPs) and through engaging them for services that contribute to the improvement of patient care. In accordance with IML the association of the innovative industry, Kyowa Kirin Pharma B.V. publishes details about transfers of value to these individuals and organizations annually.

Each Kyowa Kirin affiliate in Europe is accountable for capturing and validating data in their nation and we make one disclosure per market. This disclosure covers transfers of value between January 1st 2023 to December 31st 2023 to HCPs and HCOs and POs which are registered in Luxembourg.

2. Scope of disclosure

This disclosure includes the following transfers of value:

Sunshine Act Category	Sunshine Act sub-category	Example activities (not exhaustive)
Donations and grants	N/A	<ul style="list-style-type: none">• Donations to HCOs• Educational grants
Contribution to cost of events	Sponsorship agreements	<ul style="list-style-type: none">• Sponsorship of congresses organised by HCOs or third-parties on their behalf
	Registration fees	<ul style="list-style-type: none">• Funding of HCPs to attend congresses
	Travel and accommodation	<ul style="list-style-type: none">• HCP's travel and accommodation costs for attending congresses
Fees for service	Fees	Fees for:

		<ul style="list-style-type: none"> • Chairing or attending Advisory Boards • Speaking engagements • Medical writing
	Related expenses	Travel and accommodation expenses relating to the activities above.
Research and Development	N/A	Activities relating to: <ul style="list-style-type: none"> • planning or conduct of clinical studies • clinical trials • non-interventional studies that are prospective in nature • clinical investigator meetings • Investigation Sponsored Studies

If activities relate to retrospective non-interventional studies then they are included in Fees for Service, rather than Research and Development.

This disclosure excludes the following transfers of value:

- Informational and educational materials and items of medical utility, in line with article 9 of the EFPIA HCP/HCO Disclosure Code
- Logistical costs related to KKI-organised meetings (e.g. room hire)

As the Belgian Sunshine Act requirements only relates to transfers of value to HCPs and HCOs and POs, this disclosure does not include:

- Donations to non-HCOs

Some HCPs continue to provide advice to the healthcare community after they have retired. Generally KKI include such HCPs in the applicable regulation's definition of an HCP, however this depends on their role and ability to prescribe and influence.

3. Date of Transfers of Value

The date of the transfers of value included in this disclosure is based on date of payment (where the transfer of value is a payment).

If the transfer of value is a benefit in kind, it is based on the date the recipient received the benefit.

4. Direct and Indirect Transfers of Value

For direct transfers of value, the recipient is considered to be the person or entity receiving the money.

Kyowa Kirin Pharma B.V. also provides indirect transfers of value.

In the case of payments that are made through Clinical Research Organizations, these are included under Research and Development and reported in the aggregate.

Where a third party has been appointed by an HCO to manage an event, and where the HCO benefits from the transfer of value, these transfers of value are disclosed against the HCO.

Where third parties are appointed by KKI to make travel and accommodation arrangements for HCPs, the transfers of value are reported against the HCP who received the benefit.

5. Cross-border activities

KKI makes best efforts to capture and report all transfers of value to HCPs and HCOs with primary practice in a country with EFPIA Disclosure Code or other transparency reporting requirements. The country of disclosure is based on the HCP's principal practice or the HCO's country of registration.

6. Consent

Consent is required in Luxembourg, and is collected on an engagement -by-engagement basis. HCOs, HCPs and POs are reported on individual level when given consent, without prior consent the Transfers of Value are reported on aggregated level.



7. Disclosure

Our report of transfers of value in 2023 is published on www.betransparent.be in English.

The currency used for disclosure is Euros.

In the case that payments are made in a currency other than the reporting currency the payment amount is converted to the reporting currency using the daily exchange rate between the two currencies on the day of payment.

VAT is excluded.

Any questions regarding this disclosure should be directed to karin.vanhagen@kyowakirin.com.